Thu Sep 12 01:17:38 UTC 2024: ## Clarity Pharmaceuticals Soars on Positive SECuRE Trial Results
**Sydney, Australia -** Shares of Clarity Pharmaceuticals Ltd (ASX: CU6) surged to a new record high on Thursday, climbing 4% to $7.67, following positive updates from its SECuRE trial. This marks a 24% increase in the company’s share price since the start of last month.
The SECuRE trial, a Phase I/IIa theranostic study, aims to identify and treat patients with prostate-specific membrane antigen (PSMA)-expressing metastatic castrate-resistant prostate cancer (mCRPC) using 64Cu/67Cu-SAR-bisPSMA. The trial has shown promising results in terms of safety and efficacy, with no dose-limiting toxicities observed in the first three participants of cohort 4 who received two doses of 67Cu-SAR-bisPSMA.
Furthermore, the preliminary efficacy assessment from cohort 4 indicated a significant reduction in prostate-specific antigen (PSA) levels in participants who completed the dose-limiting toxicity (DLT) period. Two participants exhibited greater than 60% drops in PSA levels following their second dose of 67Cu-SAR-bisPSMA.
Dr Alan Taylor, Executive Chair of Clarity Pharmaceuticals, expressed his excitement about the positive results, stating that the data “reinforce our confidence that 67Cu-SAR-bisPSMA has a favourable safety profile as we consider the dosing schedule for the next phase of the trial.” He also highlighted the remarkable efficacy of the treatment, even in patients who have failed multiple previous therapies.
The positive results from the SECuRE trial have fueled investor optimism in Clarity Pharmaceuticals, driving the company’s share price to new highs. The company’s focus on developing safe and effective treatments for prostate cancer continues to attract attention in the biotech sector.
First Piper 